Thelansis

  A progressive peroxisomal disease, characterized by endocrine dysfunction, progressive myelopathy, and peripheral neuropathy, and leukodystrophy. Age of onset is highly variable, but often in the first decade. In 30–40% of boys with ALD, a CNS-based neuroinflammatory process is initiated between the ages of 4–10 years known as cerebral ALD (cALD).   Epidemiology- Based on literature research and epidemiology study of Thelansis, the diagnosed prevalence of Cerebral Adrenoleukodystrophy (CALD) are approximate ~15,600 cases in 8 major markets for the year 2020.   The competitive landscape of Cerebral adrenoleukodystrophy (CALD) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of Cerebral adrenoleukodystrophy (CALD) across 8 MM market from the center of Excellence/ Public/ Private hospitals particip...